Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2- fluorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 24, 2004, Pages 6057-6059

  Almasirad, Ali ^a   Tabatabai, Sayyed A ^b   Faizi, Mehrdad ^b   Kebriaeezadeh, Abbas ^a   Mehrabi, Nazila ^b   Dalvandi, Afshin ^a   Shafiee, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anticonvulsant; MES; PTZ; Substituted 1,3,4 oxadiazoles

Indexed keywords

2 AMINO 5 [2 (2 FLUOROPHENOXY)PHENYL] 1,3,4 OXADIAZOLE; 2 METHYLTHIO 5 [2 (2 FLUOROPHENOXY)PHENYL] 1,3,4 OXADIAZOLE; 3 ETHOXY 5 [2 (2 FLUOROPHENOXY)PHENYL] 1,2,4 TRIAZOLE; 5 [2 (2 FLUOROPHENOXY)PHENYL] 1,3,4 OXADIAZOL 2(3H) ONE; 5 [2 (2 FLUOROPHENOXY)PHENYL] 1,3,4 OXADIAZOLE 2(3H) THIONE; 5 [2 (2 FLUOROPHENOXY)PHENYL] 2,4 DIHYDRO 3H 1,2,4 TRIAZOLE 3 THIONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE RECEPTOR; DIAZEPAM; OXADIAZOLE DERIVATIVE; PENTETRAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; MOUSE; NONHUMAN; SUBSTITUTION REACTION;

ANTICONVULSANTS; DRUG EVALUATION, PRECLINICAL; MOLECULAR STRUCTURE; OXADIAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 8844281649     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.072     Document Type: Article

References (18)

1. H.N. Dogan, A. Duran, S. Rollas, G. Sener, M.K. Uysal, and D. Gülen Bioorg. Med. Chem. 10 2002 2893
2. A. Varvaresou, T. Siatra-Papastiakoudi, A. Tsotinis, A. Tsantili-Kakoulidou, and A. Vamvakides Il farmaco 53 1998 320
3. V. Michon, C. Hervé du Penhoat, F. Tombret, J.M. Gillardin, F. Lepage, and L. Berthon Eur. J. Med. Chem. 30 1995 147
4. T. Akbarzadeh, S.A. Tabatabai, M.J. Khoshnoud, B. Shafaghi, and A. Shafiee Bioorg. Med. Chem. 11 2003 769
5. A. Foroumadi, S.A. Tabatabai, G. Gitinezhad, M.R. Zarrindast, and A. Shafiee Pharm. Pharmacol. Commun. 6 2000 1
6. C.B. Chaplco, M. Myers, P.L. Myers, J.F. Saville, A.C.B. Smith, M.R. Stillings, I.F. Tulloch, D.S. Walter, and A.P. Welbourn J. Med. Chem. 29 1986 2273
7. J.M. Kane, M.A. Staeger, C.R. Dalton, F.P. Miller, M.W. Dudley, A.L. Ogden, J.H. Kehne, H.J. Ketteler, T.C. McCloskey, Y. Senyah, P.A. Chmielewaki, and J.A. Miller J. Med. Chem. 37 1994 125
8. A. Almasirad, M. Sheikhha, R. Hosseini, S.A. Tabatabai, and A. Shafiee Arch. Pharm. Pharm. Med. Chem. 337 2004 193
9. A. Shafiee, E. Naimi, P. Mansobi, A. Foroumadi, and M. Shekari J. Heterocycl. Chem. 32 1995 1235
10. F. Firoozi, K. Javidnia, M. Kamali, A. Foroumadi, and A. Shafiee J. Heterocycl. Chem. 32 1995 123
11. B.H. Goswami, J.C. Sarmah Kataky, and J.N. Baruah J. Heterocycl. Chem. 21 1984 1225
12. C. Morpygo Arzneim.-Forsch. 11 1971 1727
13. H.C. Jackson, H.C. Hansen, M. Kristiansen, P.D. Suzdak, H. Klitgaar, M.E. Judge, and D.B. Swedberd Eur. J. Pharmacol. 306 1996 21
14. J.O. McNamara J.G. Hardman L.E. Limbird Goodman and Gilman's the Pharmacological Basis of Therapeutics 2001 McGraw-Hill New York 523 524
15. B.S. Meldrum B.S. Meldrum R.J. Porter New Anticonvulsant Drugs (Current Problems in Epilepsy) Vol. 4 1986 John Libbey and Company Ltd London 31 48
16. J. Gupa Indian J. Physiol. Pharmacol. 43 1 1999 31
17. H.G. Vogel, and W.H. Vogel Drug Discovery and Evaluation 1997 Springer Berlin pp 260-261
18. S.G. Piredda, J.H. Woodhead, and E.A. Swinyard J. Pharmacol. Exp. Ther. 232 1985 741